TNGX
Tango Therapeutics Inc
22.60$
+3.4%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Cash Flow
Tango Therapeutics Inc (TNGX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -39 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -12 | -11 | 111 | -18 | -14 | -7.5 | -21 | -17 | -30 | -32 | -20 | -28 | -35 | -24 | -31 | -27 | -38 | -24 | -33 | -37 | -42 | -37 | -31 | -30 | -44 | -39 | -144 | |
| 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.3 | 0.3 | 0.3 | 0.4 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.5 | 0.5 | 0.4 | 1.9 | |
| 0.4 | 0.4 | 0.4 | 0.5 | 1.0 | 1.2 | 3.4 | 2.3 | 3.2 | 3.4 | 3.8 | 3.8 | 4.2 | 5.1 | 4.9 | 4.9 | 6.7 | 7.5 | 7.2 | 7.5 | 7.3 | 6.6 | 6.6 | 6.0 | 11 | 17 | 40 | |
| 0.6 | 0.6 | 0.6 | – | 1.3 | 1.5 | 3.7 | 2.7 | 3.3 | 3.8 | 4.4 | 3.3 | 3.3 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| -1.4 | 1.4 | 1.8 | -10 | -3.0 | -4.7 | -5.9 | 2.2 | -8.4 | -11 | 4.6 | -4.0 | -12 | -9.5 | -16 | -0.8 | -6.8 | -6.0 | -12 | -7.1 | -10 | -5.2 | -54 | 2.4 | -10 | -0.9 | -63 | |
| 0.0 | 0.5 | 0.1 | 0.5 | 0.2 | 0.2 | 0.8 | 0.7 | 1.6 | 1.8 | 3.3 | 1.0 | 0.6 | 0.7 | 0.0 | 0.2 | 0.2 | 0.3 | 0.1 | 0.1 | 0.1 | 0.6 | 0.2 | 0.2 | 0.0 | 0.0 | 0.4 | |
| 12 | -28 | -70 | -59 | 21 | -6.6 | -152 | -45 | -12 | 35 | 15 | -13 | 32 | 33 | -57 | 34 | -11 | 13 | 33 | 52 | 31 | 17 | 47 | -136 | 9.6 | -446 | -525 | |
| – | – | – | – | – | – | – | – | 0.3 | – | – | – | 0.1 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 30 | 30 | 51 | -0.1 | 30 | -0.7 | 328 | -0.1 | 0.3 | 0.7 | 0.1 | 0.5 | 0.1 | 0.6 | 80 | 1.5 | 43 | 1.3 | 2.4 | 1.0 | 0.0 | 0.6 | 2.5 | 219 | 80 | 673 | 974 | |
| -0.2 | -9.5 | 93 | -77 | 37 | -15 | 154 | -62 | -41 | 4.7 | -4.3 | -40 | -3.3 | 8.8 | -7.5 | 7.9 | -6.1 | -9.6 | 1.6 | 16 | -11 | -19 | 19 | 54 | 45 | 188 | 306 | |
| -12 | -11 | 111 | -19 | -14 | -7.7 | -22 | -18 | -31 | -33 | -23 | -29 | -36 | -25 | -31 | -28 | -38 | -24 | -34 | -37 | -42 | -37 | -31 | -30 | -44 | -39 | -144 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.